PGNX News and Press, Progenics Pharmaceuticals Inc. From 09/03/19

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting PyL TM ( 18 F-DCFPyL) has been...

Progenics Pharmaceuticals ( PGNX ) recently reported their Q2 earnings report with a miss on EPS and beat on revenue. Although the company reported a 157% year-over-year growth, they only dosed two patients with AZEDRA. In fact, Azedra sales came in at $0.3M, whereas RELISTOR royalty i...

ALPHARETTA, Ga. , Aug. 12, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other members of its group, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised of successful specialty phar...

Progenics Pharmaceuticals, Inc. (PGNX) Q2 2019 Results Earnings Conference Call August 9, 2019 08:30 AM ET Company Participants Melissa Downs - Head of Investor Relations Mark Baker - Chief Executive Officer Asha Das - Chief Medical Officer Bryce Tenbarge - Senior Vice Presid...

Progenics Pharmaceuticals ( PGNX ) Q2 results : Revenues: $10M (+156.4%); Azedra sales: $0.3M; Royalty income: $3.6M (+2.9%); License and other revenue: $6.1M. More news on: Progenics Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

Progenics Pharmaceuticals (NASDAQ: PGNX ): Q2 GAAP EPS of -$0.23 misses by $0.04 . More news on: Progenics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Recorded First Revenues for AZEDRA ® ; CMS Grants New Technology Add-On Payment of Up to $98,150 per Therapeutic Dose for Inpatient Use of AZEDRA Enrollment Completed Ahead of Schedule in Phase 3 CONDOR Trial of PyL TM ( 18 F-DCFPyL); Topline Data Expected by Year End 2019 First P...

Board Accepts Resignations of Directors Peter J. Crowley and Michael D. Kishbauch, Effective October 17, 2019 Board Names New Committee Chairs Board Adopts Stock Ownership Guidelines for Directors and Officers Members of Newly Constituted Nominating and Corporate Governanc...

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the Centers for Medicare & Medicaid Services (CMS) h...

Top-line Data Now Expected by Year End Reaches Alignment with FDA on Regulatory Path; Company to Submit NDA Following Positive CONDOR Data Completed Enrollment in Pivotal Phase 3 Trial in Eight Months NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (N...